Supernus Pharma (SUPN) Misses Q3 EPS by 6c, Revenues Miss; Lowers FY19 Sales Views, Reports Topline Data from Ph. 3 Study of SPN-810 Nov 5, 2019 04:57PM
Supernus Pharma (SUPN) Phase III P301 trial of SPN-810 for treatment of IA in ADHD patients 6 to 11 years old did not meet its primary endpoint Nov 5, 2019 04:56PM
Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients Nov 5, 2019 04:55PM
Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients Nov 5, 2019 04:55PM
StreetInsider.com Pre-Open Movers 11/30: (CBK) (TLAB) (ULTA) Higher; (VRSN) (ZUMZ) (YUM) Lower (more...) Nov 30, 2012 09:28AM